UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from HC Wainwright


Share on StockTwits

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Thursday, AnalystRatings.com reports.

URGN has been the subject of a number of other reports. JPMorgan Chase & Co. reduced their price target on shares of UroGen Pharma from $31.00 to $26.00 in a research report on Monday, September 21st. Oppenheimer reduced their price target on shares of UroGen Pharma from $48.00 to $40.00 in a research report on Tuesday, November 10th. ValuEngine downgraded shares of UroGen Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 26th. Finally, BidaskClub upgraded shares of UroGen Pharma from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 7th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. UroGen Pharma has a consensus rating of “Hold” and an average target price of $39.40.

Shares of NASDAQ:URGN opened at $20.29 on Thursday. The company has a market cap of $424.00 million, a P/E ratio of -3.30 and a beta of 1.69. UroGen Pharma has a 52 week low of $13.12 and a 52 week high of $35.00. The company has a 50-day moving average price of $19.30 and a 200 day moving average price of $21.73.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Monday, November 9th. The company reported ($1.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.47) by $0.16. The firm had revenue of $3.46 million during the quarter, compared to analyst estimates of $3.21 million. As a group, analysts predict that UroGen Pharma will post -6.14 earnings per share for the current fiscal year.

In other UroGen Pharma news, CEO Elizabeth A. Barrett acquired 10,000 shares of the company’s stock in a transaction dated Monday, December 14th. The stock was acquired at an average cost of $18.50 per share, with a total value of $185,000.00. Following the purchase, the chief executive officer now directly owns 229,117 shares in the company, valued at approximately $4,238,664.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 12.00% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. UBS Asset Management Americas Inc. grew its stake in UroGen Pharma by 17.3% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 22,400 shares of the company’s stock worth $432,000 after acquiring an additional 3,299 shares during the period. Phoenix Holdings Ltd. grew its stake in UroGen Pharma by 0.5% in the 3rd quarter. Phoenix Holdings Ltd. now owns 901,979 shares of the company’s stock worth $16,405,000 after acquiring an additional 4,515 shares during the period. BlackRock Inc. grew its stake in UroGen Pharma by 1.4% in the 3rd quarter. BlackRock Inc. now owns 1,485,601 shares of the company’s stock worth $28,657,000 after acquiring an additional 19,796 shares during the period. Aperio Group LLC grew its stake in shares of UroGen Pharma by 36.6% during the 3rd quarter. Aperio Group LLC now owns 22,641 shares of the company’s stock valued at $437,000 after buying an additional 6,066 shares during the period. Finally, California Public Employees Retirement System grew its stake in shares of UroGen Pharma by 2.6% during the 3rd quarter. California Public Employees Retirement System now owns 40,200 shares of the company’s stock valued at $775,000 after buying an additional 1,000 shares during the period. 69.95% of the stock is owned by hedge funds and other institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.

Further Reading: Options Trading – What is a Straddle?

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.